Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-Cell Lymphoma, Leg-Type: A Case Report

Chemotherapy. 2024;69(1):23-26. doi: 10.1159/000534784. Epub 2023 Nov 1.

Abstract

Introduction: For primary cutaneous diffuse large B-cell lymphoma, leg-type (PCDLBCL-LT), there are no uniform recommendations for second-line treatment in case of relapse.

Case presentation: Here, we present the case of an elderly relapsed/refractory PCDLBCL-LT patient who obtained a prolonged clinical complete remission with lenalidomide.

Conclusion: Lenalidomide as single agent led to an unexpected long complete response with manageable toxicity.

Keywords: Leg-type; Lenalidomide; Primary cutaneous diffuse large B-cell lymphoma; Remission.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Humans
  • Leg* / pathology
  • Lenalidomide / therapeutic use
  • Lymphoma, Large B-Cell, Diffuse* / diagnosis
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Neoplasm Recurrence, Local / drug therapy
  • Pathologic Complete Response
  • Treatment Outcome

Substances

  • Lenalidomide